<DOC>
	<DOCNO>NCT00073814</DOCNO>
	<brief_summary>Study Daily Dosing Levalbuterol , Racemic Albuterol , Placebo Pediatric Subjects Asthma</brief_summary>
	<brief_title>Study Daily Dosing With Levalbuterol , Racemic Albuterol , Placebo Pediatric Subjects With Asthma</brief_title>
	<detailed_description>This Phase III , double-blind , randomize , placebo- active-controlled , multicenter , parallel-group study 6 week duration . Seven day QID single-blind , placebo administration ( via HFA MDI ) follow 28 day QID , double-blind treatment . A follow-up visit require subject , opinion investigator , clinically significant find Visit 6 /ET would put subject risk . A final follow phone evaluation conduct 7 day completion Visit 6/ET . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Inclusion Criteria Subject subject 's p/l guardian must willing able comply study procedure visit schedule Subject , male female , age 4 11 yr Female subject 8 yr old negative serum pregnancy test Must document diagnosis asthma minimum 6 month prior study start Must stable baseline asthma use Badrenergic agonist , and/or antiasthma antiinflammatory medication , and/or overthecounter asthma medication least 6 mo . prior study start Must good health exception reversible airway disease suffer chronic condition might affect respiratory function Must chest Xray diagnostic pneumonia , atelectasis , pulmonary fibrotic disease , pneumothorax , chronic obstructive pulmonary disease etc Subject 's p/l guardian must able complete diary card medical event calendar reliably daily basis , understand dose instruction questionnaire completion , demonstrate use MiniWright PEF meter Exclusion Criteria Female subject pregnant lactating Have participate investigational drug study within 30 day prior study start , currently participate another clinical trial Schedule prevents take first daily dose study medication and/or start study visit 9 AM Have travel commitment study would interfere trial measurement compliance Have history hospitalization asthma within 60 day prior study start , schedule inpatient hospitalization , include elective surgery course trial Have know sensitivity levalbuterol racemic albuterol , excipients contain formulation Subject use prescription drug albuterol sulfate administration contraindicate Have currently diagnose lifethreatening asthma define history asthma episodes require intubation , associate hypercapnia , respiratory arrest , hypoxic seizure within 3 mo . prior study start Have history cancer Subject hyperthyroidism , diabetes , hypertension , cardiac disease seizure disorder currently well control medication may interfere successful completion protocol Have history substance abuse drug abuse within 12 month precede V1 positive urine drug screen study start Have document history bronchopulmonary aspergillosis form allergic alveolitis Has suffer clinically significant upper low respiratory tract infection 2 wks prior study start Have history cigarette smoking use tobacco product Subject relative staff member</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>levalbuterol</keyword>
	<keyword>pediatric</keyword>
	<keyword>asthma</keyword>
</DOC>